Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

BACKGROUND AND PURPOSE: Incretin‐based therapies based on glucagon‐like peptide‐1 (GLP‐1) receptor agonists are effective treatments of type 2 diabetes. Abundant research has focused on the development of long‐acting GLP‐1 receptor agonists. However, all GLP‐1 receptor agonists in clinical use or de...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Br J Pharmacol
Egile Nagusiak: Han, Jing, Fei, Yingying, Zhou, Feng, Chen, Xinyu, Zhang, Ying, Liu, Lin, Fu, Junjie
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2018
Gaiak:
Research Papers
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5773971/
https://ncbi.nlm.nih.gov/pubmed/29171021
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.14107
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak